Mc Laughlin, Anna M.
Hess, Dagmar
Michelet, Robin
Colombo, Ilaria
Haefliger, Simon
Bastian, Sara
Rabaglio, Manuela
Schwitter, Michael
Fischer, Stefanie
Eckhardt, Katrin
Hayoz, Stefanie
Kopp, Christoph
Klose, Marian
Sessa, Cristiana
Stathis, Anastasios
Halbherr, Stefan
Huisinga, Wilhelm
Joerger, Markus
Kloft, Charlotte
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
https://doi.org/10.1007/s00280-024-04679-z
Funding for this research was provided by:
InnoMedica, Swiss State Secretary for Education, Research and Innovation (SERI), Swiss Cancer Research Foundation (SCS), Swiss Cancer League
Freie Universität Berlin
Article History
Received: 4 February 2024
Accepted: 18 May 2024
First Online: 15 June 2024
Declarations
:
: C.K. and W.H. report grants from an industry consortium (AbbVie Deutschland GmbH & Co. KG, Astra Zeneca Ltd., Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA, Novo Nordisk and Sanofi) for the PharMetrX PhD program. C.K. reports grants for the Innovative Medicines Initiative-Joint Undertaking (“DDMoRe”), Diurnal Ltd., the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (JPIAMR) and from the European Commission within the Horizon 2020 framework program (“FAIR”). A.M.L. is a current employee of Pharmetheus AB and a paid consultant to multiple pharmaceutical companies. I.C. provided advisory/expert opinion for GSK, Novartis, Astra Zeneca, and MSD and recceived travel grants from Tesaro and institutional grants for clinical trials (Principal Investigator): MSD, Bayer, Oasmia. A.T. received institutional research funding from Innomedica, MEI Pharma, Merck, Bayer, Roche, Novartis, Pfizer, ADC Therapeutics, and Eli Lilly, and consulting fees from Bayer, Eli Lilly, Roche, and Novartis. M.J. is investigators in clinical trials for AstraZeneca, Basilea Pharmaceutica, Bayer, BMS, Daiichi Sankyo, Immunophotonics, Innomedia, Janssen, Lilly, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, and received travel grants from BSM, Roche, MSD. S.H. provided adivsory/expert opinion for Bayer, Novartis, Lilly, AstraZeneca, and MSD. A.S. received institutional funding for clinical trials for AbbVie, ADC Therapeutics, Amgen, AstraZeneca, Bayer, Cellestia, Incyte, Loxo Oncology, Merck MSD, Novartis, Pfizer, Philogen and Roche, provided paid consultancy services for Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, and Lox Oncology, and received travel grants from Incyte and AstraZeneca. The other authors declare that they have no conflict of interest.
: The institutional review board/ethics committees of participating centers approved the trial. The trial followed the ethical principles of the Declaration of Helsinki, the International Conference on Harmonization Guideline for Good Clinical Practice, and local regulations.
: All patients provided written informed consent before enrollment.
: Not applicable.